What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Pathology
Talmadge E. King mostly deals with Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Internal medicine, Interstitial lung disease and Surgery.
His biological study spans a wide range of topics, including Respiratory disease, Intensive care, Intensive care medicine and FEV1/FVC ratio.
His work carried out in the field of Pulmonary fibrosis brings together such families of science as Biopsy, Radiology, Cause of death and Respiratory failure.
The various areas that Talmadge E. King examines in his Internal medicine study include Gastroenterology and Cardiology.
His Interstitial lung disease research includes elements of Physical therapy and Pathology.
He focuses mostly in the field of Surgery, narrowing it down to matters related to Placebo and, in some cases, Pirfenidone, Interim analysis and Azathioprine.
His most cited work include:
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management (4402 citations)
- American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias (3012 citations)
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias (1870 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Idiopathic pulmonary fibrosis, Internal medicine, Pathology, Interstitial lung disease and Lung.
He interconnects Pulmonary fibrosis, FEV1/FVC ratio and Intensive care medicine in the investigation of issues within Idiopathic pulmonary fibrosis.
His Internal medicine research includes elements of Gastroenterology, Placebo and Surgery.
His biological study spans a wide range of topics, including Respiratory disease and Bronchoalveolar lavage.
Talmadge E. King has included themes like Survival rate, Hypersensitivity pneumonitis, Pulmonary function testing, Rheumatoid arthritis and Prospective cohort study in his Interstitial lung disease study.
The various areas that Talmadge E. King examines in his Lung study include Disease and Immunology.
He most often published in these fields:
- Idiopathic pulmonary fibrosis (54.79%)
- Internal medicine (40.18%)
- Pathology (36.99%)
What were the highlights of his more recent work (between 2013-2020)?
- Idiopathic pulmonary fibrosis (54.79%)
- Internal medicine (40.18%)
- Interstitial lung disease (26.03%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Idiopathic pulmonary fibrosis, Internal medicine, Interstitial lung disease, Pirfenidone and Surgery.
Talmadge E. King carries out multidisciplinary research, doing studies in Idiopathic pulmonary fibrosis and In patient.
His work deals with themes such as Gastroenterology and Placebo, which intersect with Internal medicine.
His study in Interstitial lung disease is interdisciplinary in nature, drawing from both Radiology, Radiography, Rheumatoid arthritis and Pathology.
In his study, Pulmonary fibrosis and Intervention is strongly linked to Nintedanib, which falls under the umbrella field of Pirfenidone.
In his study, Nausea, Discontinuation and Rash is inextricably linked to Adverse effect, which falls within the broad field of Surgery.
Between 2013 and 2020, his most popular works were:
- A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis (1848 citations)
- Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. (315 citations)
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials (213 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His scientific interests lie mostly in Idiopathic pulmonary fibrosis, Internal medicine, Surgery, Interstitial lung disease and Pirfenidone.
The concepts of his Idiopathic pulmonary fibrosis study are interwoven with issues in Prospective cohort study, Disease, Pulmonary function testing and Intensive care medicine.
His Intensive care medicine research integrates issues from Patient advocacy and Immunology.
Talmadge E. King studied Internal medicine and Placebo that intersect with FEV1/FVC ratio and Vital capacity.
Talmadge E. King specializes in Interstitial lung disease, namely Usual interstitial pneumonia.
The Pirfenidone study combines topics in areas such as Adverse effect and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
